OpenAI and Longevity: Extending Human Life

GPT-4b Micro: OpenAI's New AI for Longevity Research

OpenAI has developed a new AI model, designated GPT-4b micro, in collaboration with Retro Biosciences. This partnership focuses on advancements in longevity science, with the goal of potentially extending the human lifespan by a decade, as reported by the MIT Technology Review.

Collaboration with Retro Biosciences

Retro Biosciences, a startup supported by Sam Altman, has been engaged in research with OpenAI for approximately one year. This collaborative effort centers around the application of artificial intelligence to biological challenges.

Re-engineering Proteins with AI

The GPT-4b micro model is designed to re-engineer proteins, specifically focusing on the Yamanaka factors. These factors have the capability to transform mature human skin cells into induced pluripotent stem cells, exhibiting characteristics of younger cells.

Retro Biosciences posits that these proteins represent a significant advancement towards the future of human organ creation and the provision of readily available replacement cells.

Distinction from AlphaFold

While sharing some similarities with Google’s AlphaFold – a system recognized with a Nobel Prize for predicting protein structures – the GPT-4b micro model operates with a distinct approach.

Notably, this represents OpenAI’s inaugural model specifically engineered for applications within the field of biological research.

Future Research and Release

OpenAI and Retro Biosciences have jointly announced their intention to publish research detailing the GPT-4b micro model and its resulting outputs, according to the MIT Technology Review.

This release is anticipated to contribute to the broader scientific community’s understanding and utilization of AI in biological applications.